27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Integra LifeSciences Holdings Corp (NASDAQ:IART) reported Q1 FY23 sales of $388.8 million, which increased 1.1% Y/Y on a reported basis and increased 4.6% on an organic basis, beating the consensus of $373.21 million and the management guidance of $370 million-$376 million.
Adjusted EPS stood at $0.74, in line with the Street estimate and management outlook of $0.72-$0.76.
The adjusted gross margin was 67.3%, compared to 67.7% in the prior year.
Adjusted EBITDA was $92.3 million, or 24.2% of revenue, compared to $93.5 million, or 24.8% of revenue, in the prior year.
Guidance: For Q2 FY23, Integra LifeSciences expects revenues of $396 million-$400 million compared to the consensus of $404.78 million.
Adjusted EPS is expected to be $0.75-$0.79 versus the consensus of $0.85, including the impact of the acceleration of the Boston quality system upgrades from the second half of the year into the second quarter.
For FY23, the company reaffirms revenues guidance of $1.60-$1.62 billion and adjusted EPS of $3.43-$3.51 compared to the consensus of $1.62 billion and $3.52, respectively.
Price Action: IART shares are down 8.46% at $53.98 on the last check Wednesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!